March 12, 2019

Gene Editing Stocks

The Fool looks briefly at three gene editing stocks, the most interesting of which is Editas.  The company's lead drug looks to cure genetic blindness, but it is only in Phase 1 trials.  However, the drug looks to be given the fast track by the FDA.   

No comments: